Biodexa has enrolled the initial two subjects in the Phase III Serenta study of eRapa, involving individuals with FAP.

Anocca has secured approximately Skr440m (around $46m) to primarily support the early-stage clinical trials of VIDAR-1.

This is the latest hit for Pfizer’s sickle cell disease portfolio after pulling Oxbryta from the market in 2024.

THL Partners has announced its agreement to purchase Headlands Research, a clinical trial sites network, from KKR-managed ...

MASLD is among the most common types of chronic liver disease and is estimated to affect 30% of the global population.

As antimicrobial resistance (AMR) escalates and chronic viral infections like human immunodeficiency virus (HIV) and herpes ...

Vendanta's CEO also announced the company is cutting 20% of its workforce as a result of the Phase II UC trial failure.

Aligos has initiated dosing in the Phase II B-SUPREME trial of its ALG-000184 in people with chronic hepatitis B virus (HBV) ...

The Phase II STARLIGHT study (NCT05417126) found that a single intravitreal injection of gene-agnostic MCO-010 in six ...

Marea Therapeutics has enrolled the first subject in the MAR-201 Phase I trial of MAR002, aimed at treating acromegaly.

Stoke Therapeutics and Biogen have dosed the first subject in the Phase III EMPEROR trial of zorevunersen for Dravet syndrome ...

Elicio's mKRAS-targeting cancer vaccine reduced the risk of death by 77% by activating the anti-tumour mechanisms of key ...